2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  3. Antibody-Drug Conjugates (ADCs) EGFR
  4. Disitamab vedotin

Disitamab vedotin  (Synonyms: RC48)

製品番号: HY-P9985 純度: 98.90%
COA 取扱説明書 Technical Support

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 2136633-23-1

容量 価格（税別） 在庫状況 数量
1 mg $420 在庫あり
5 mg $1250 在庫あり
10 mg $1880 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Disitamab vedotin 関連抗体

Top Publications Citing Use of Products

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Disitamab vedotin (DV, 0.25 μg/mL) reduced the overall cell number of HER2-positive JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Unlike the parental cells, which were sensitive to XMT-1522 and Disitamab vedotin (DV, 0.0001, 0.0006, 0.003, 0.016, 0.08, 0.4, 1, 2, and 10 μg/mL; 5 days), both D1 and D2 daughter cells that emerged from the DTP-PGCC were resistant to these drugs. D1, daughter-1 cells (one prior ADC treatment); D2, daughter-2 cells (two prior ADC treatments). ∗∗, p < 0.01; ∗∗∗, p < 0.001.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    Disitamab vedotin (DV, 50 μg/mL, 15 or 30 min) increased T-DM1 internalization into JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In JIMT-1 xenografts, the combination of Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) plus T-DM1, as well as DV plus T-DXd, inhibited tumor growth more effectively than the corresponding single treatments.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In macroscopic JIMT-1 xenografts, tumors that relapsed after T-DM1 treatment and subsequently responded to Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) but later progressed had lost HER2 expression. A: PBS; B: relapsed after T-DM1, progressed on T-DM1; C: relapsed after T-DM1, progressed on DV; D: relapsed after T-DM1, progressed on T-DXd.

    EGFR アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity[1].

    IC50 & Target[1]

    HER2

     

    体外実験

    The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Disitamab vedotin 関連抗体
    臨床実験
    分子量

    149000 (average)

    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    [Disitamab vedotin]
    輸送条件

    Shipping with dry ice.
    保管条件

    Please store the product under the recommended conditions in the Certificate of Analysis.
    純度とドキュメンテーション

    純度: 98.90%

    COA (232 KB) Others (223 KB) SEC-HPLC (77 KB)

    取扱説明書 (2659 KB)
    参考文献
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Disitamab vedotin Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Disitamab vedotin2136633-23-1RC48RC 48RC-48Antibody-Drug Conjugates (ADCs)EGFRAntibody-Drug ConjugatesEpidermal growth factor receptorErbB-1HER1anti-HER2antibodyMMAEantitumorimmunitygastriccancerbreastInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Disitamab vedotin
    製品番号:
    HY-P9985
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.